132 related articles for article (PubMed ID: 38163953)
1. Identification of Candidate mRNA Genes and Their Potential MicroRNA Targets in Lung Cancer Induced by Smoking Tobacco.
Mishra AK; Mumtaz N; Misra MK
Front Biosci (Schol Ed); 2023 Nov; 15(4):13. PubMed ID: 38163953
[TBL] [Abstract][Full Text] [Related]
2. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
Gasparini P; Cascione L; Landi L; Carasi S; Lovat F; Tibaldi C; Alì G; D'Incecco A; Minuti G; Chella A; Fontanini G; Fassan M; Cappuzzo F; Croce CM
Proc Natl Acad Sci U S A; 2015 Dec; 112(48):14924-9. PubMed ID: 26627242
[TBL] [Abstract][Full Text] [Related]
3. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
[TBL] [Abstract][Full Text] [Related]
4. Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.
Hassanein SS; Ibrahim SA; Abdel-Mawgood AL
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830377
[TBL] [Abstract][Full Text] [Related]
5. The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients.
Szpechcinski A; Florczuk M; Duk K; Zdral A; Rudzinski S; Bryl M; Czyzewicz G; Rudzinski P; Kupis W; Wojda E; Giedronowicz D; Langfort R; Barinow-Wojewodzki A; Orlowski T; Chorostowska-Wynimko J
Cell Mol Life Sci; 2019 Sep; 76(18):3641-3656. PubMed ID: 30953094
[TBL] [Abstract][Full Text] [Related]
6. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
[TBL] [Abstract][Full Text] [Related]
7. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
8. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
9. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
10. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
[TBL] [Abstract][Full Text] [Related]
11. Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan.
Ogawa K; Koh Y; Kaneda H; Izumi M; Matsumoto Y; Sawa K; Fukui M; Taniguchi Y; Yoshimoto N; Tamiya A; Ando M; Kubo A; Isa SI; Saka H; Matsumura A; Kawaguchi T
BMJ Open; 2020 Sep; 10(9):e035615. PubMed ID: 32907893
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
[TBL] [Abstract][Full Text] [Related]
13. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
14. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.
Deng LL; Deng HB; Lu CL; Guo Y; Wang D; Yan CH; Lv X; Shao YX
J Cancer Res Clin Oncol; 2014 Dec; 140(12):2097-105. PubMed ID: 24994038
[TBL] [Abstract][Full Text] [Related]
15. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.
Varghese AM; Sima CS; Chaft JE; Johnson ML; Riely GJ; Ladanyi M; Kris MG
J Thorac Oncol; 2013 Jan; 8(1):123-5. PubMed ID: 23242442
[TBL] [Abstract][Full Text] [Related]
16. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
17. Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer.
Wang X; Ricciuti B; Nguyen T; Li X; Rabin MS; Awad MM; Lin X; Johnson BE; Christiani DC
Cancer Res; 2021 May; 81(9):2566-2573. PubMed ID: 33653773
[TBL] [Abstract][Full Text] [Related]
18. Identification of LGR4 as a prognostic biomarker in KRAS-mutant lung adenocarcinoma: Evidence from integrated bioinformatics analysis.
Dodin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36084. PubMed ID: 37986325
[TBL] [Abstract][Full Text] [Related]
19.
Yang D; Feng Y; Lu H; Chen K; Xu J; Li P; Wang T; Xia D; Wu Y
J Zhejiang Univ Sci B; 2023 Feb; 24(2):143-156. PubMed ID: 36751700
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
